Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Holding EDIT?
Track your performance easily
EDIT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.16 - $11.58
Previous Close$1.23
Volume2.79M
Average Volume (3M)2.49M
Market Cap
$101.53M
Enterprise Value-$125.07M
Total Cash (Recent Filing)$265.09M
Total Debt (Recent Filing)$38.49M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Feb 26, 2025EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding82,548,099
10 Day Avg. Volume3,606,564
30 Day Avg. Volume2,492,793
Standard Deviation0.28
R-Squared0.12
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.58
Price to Sales (P/S)1.62
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.03
Enterprise Value/Gross Profit-1.60
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$4.11Price Target Upside239.67% Upside
Rating ConsensusHold
Number of Analyst Covering17
Editas Medicine News
Bulls Say, Bears Say
Bulls Say
Financial ManagementEditas plans to extend their cash runway into 2Q27 through the initiating of cost savings measures and reduction in workforce, indicating strong financial management.
Gene Editing TechnologyEditas Medicine presented promising preclinical in vivo data showing gene upregulation therapies success in humanized mice.
Strategic PartnershipsEditas Medicine has announced a partnership with Genevant Sciences to advance additional in vivo assets, which may lead to significant milestone payments up to $238 million.
Bears Say
Competitive PressureBeam Therapeutics will be presenting data at ASH, showing >60% HbF induction in patients, which exceeds the levels reported in Editas's RUBY trial and may exert competitive pressure on reni-cel.
Strategic ShiftEditas Medicine announced a strategic transition to focus entirely on development of in vivo therapies after failing to find a partner for its clinical-stage ex vivo-edited sickle cell/beta thalassemia therapy reni-cel.
Workforce ReductionEditas announced their decision to end the development of reni-cel, an ex vivo gene editor for the treatments of Sickle Cell Disease (SCD) and β-Thalassemia (TDT) after their search for a commercial partner failed, resulting in a ~65% reduction in workforce.
---
Ownership Overview
0.85% Insiders
14.94% Mutual Funds
12.70% Other Institutional Investors
58.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDIT FAQ
What was Editas Medicine Inc’s price range in the past 12 months?
Editas Medicine Inc lowest stock price was $1.16 and its highest was $11.58 in the past 12 months.
What is Editas Medicine Inc’s market cap?
Currently, no data Available
When is Editas Medicine Inc’s upcoming earnings report date?
Editas Medicine Inc’s upcoming earnings report date is Feb 26, 2025 which is in 60 days.
How were Editas Medicine Inc’s earnings last quarter?
Editas Medicine Inc released its earnings results on Nov 04, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.747 by -$0.003.
Is Editas Medicine Inc overvalued?
According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued.
Does Editas Medicine Inc pay dividends?
Editas Medicine Inc does not currently pay dividends.
What is Editas Medicine Inc’s EPS estimate?
Editas Medicine Inc’s EPS estimate is -$0.34.
How many shares outstanding does Editas Medicine Inc have?
Editas Medicine Inc has 82,548,096 shares outstanding.
What happened to Editas Medicine Inc’s price movement after its last earnings report?
Editas Medicine Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.747. Following the earnings report the stock price went down -1.031%.
Which hedge fund is a major shareholder of Editas Medicine Inc?
Among the largest hedge funds holding Editas Medicine Inc’s share is Woodline Partners LP. It holds Editas Medicine Inc’s shares valued at 3M.
---
Editas Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.11 (239.67% Upside)
$4.11 (239.67% Upside)
Blogger Sentiment
Bullish
EDIT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 84.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.46%
12-Months-Change
Fundamentals
Return on Equity
-78.56%
Trailing 12-Months
Asset Growth
-35.09%
Trailing 12-Months
Company Description
Editas Medicine Inc
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
---
EDIT Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in both clinical trials and in vivo pipeline development. Financial stability was assured despite a higher burn rate. However, challenges such as increased expenses and regulatory issues around fertility support present hurdles. Overall, the company's advancements in gene editing and robust clinical trial outcomes provide a positive outlook.Read More>---
EDIT Stock 12 Month Forecast
Average Price Target
$4.11
▲(239.67% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering EDIT
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-9.44%
assigned a buy rating 15 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -9.44% per trade.
---